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Background: Uncontrolled proteolysis contributes to cell injury and organ dysfunction in animal models of circulatory
shock. We investigated in humans the relationship between septic shock, proteolysis, and outcome.
Methods: Intensive care patients with septic shock (n¼29) or sepsis (n¼6) and non-hospitalised subjects (n¼9) were
recruited as part of the prospective observational trial ‘ShockOmics’ (ClinicalTrials.gov Identifier NCT02141607). A mass
spectrometry-based approach was used to analyse the plasma peptidomes and the origin of circulating peptides from
proteolysis in the enrolled subjects.
Results: Evidence of systemic proteolysis was indicated by a larger number of circulating peptides in septic shock pa-
tients, compared with septic patients and non-hospitalised healthy subjects. The peptide count and abundance in the
septic shock patients were greater in patients who died (n¼6) than in survivors (n¼23), suggesting an association between
magnitude of proteolysis and outcome. In silico analysis of the peptide sequences and of the sites of cleavage on the
proteins of origin indicated a predominant role for serine proteases, such as chymotrypsin, and matrix metalloproteases
in causing the observed proteolytic degradation.
Conclusions: Systemic proteolysis is a novel fundamental pathological mechanism in septic shock. Plasma peptidomics
is proposed as a new tool to monitor clinical trajectory in septic shock patients.
Clinical trial registration: NCT02141607.
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Editor’s key points
 Recent data have suggested that systemic proteolysis
occurs in sepsis but its clinical relevance is uncertain.
 In this observational study, circulating concentrations
of peptide were increased in patients with septic
shock compared with patients with sepsis and healthy
controls.
 There was an association between increased peptide
concentrations and mortality in patients with septic
shock.
 Further translational and clinical research into the
possible role of proteolysis in sepsis is needed.
1066 - Bauza-Martinez et al.Sepsis is a life-threatening condition caused by a dysregulated
host response to infection.1 Septic shock is the most severe
form of sepsis, characterised by circulatory failure and tissue
injury, and associated with high mortality.2
Despite longstanding efforts to develop new treatments for
septic shock, interventions are still based on haemodynamic
support, antibiotics and anti-infective drugs, and source con-
trol (e.g. surgery). To date, no therapy addresses the root cause
of septic shock, largely because of an incomplete under-
standing of the cascade leading to multiorgan dysfunction.
Uncontrolled proteolysis has recently been proposed as a
fundamental pathological mechanism in shock, possibly
mediated by digestive enzymes.3e9 Enteral blockade of
pancreatic proteases in animals mitigates organ injury and
improves outcome.3e9 I.V. serine protease blockade has also
shown some efficacy in severe sepsis.10 Further, we recently
reported the occurrence of systemwide proteolysis and the
appearance of a large number of circulating peptides in a rat
model of shock.8
The objectives of this study are: (i) to investigate proteolysis
in septic shock patients compared with septic patients
without shock and healthy donors by assessment of plasma
peptide concentrations from mass spectrometry-based pepti-
domics, and by in silico analysis of proteolytic activity; and (ii)
to determine the association between proteolysis and in-
hospital mortality in septic shock.Methods
Study design and participants
This study is part of the prospective observational trial
‘ShockOmics’ (ClinicalTrials.gov Identifier NCT02141607)11 and
was approved by: the Geneva Regional Research Ethics Com-
mittee (study number 14-041); the Ethical committee of
Ho^pital Erasme-Universite Libre De Bruxelles (study number
P2014/171), and the Mutua Terrassa Hospital Institutional Re-
view Board (study number EO/1407).
Adult (>18 yr old) patients admitted between October 2014
and March 2016 to the ICU of Geneva University Hospitals,
Geneva, Switzerland (38-bed, mixed) and Erasme University
Hospital, Brussels, Belgium (36-bed,mixed) with septic shock12
diagnosis, Sequential Organ Failure Assessment (SOFA) score
6, arterial lactate 2 mmol L1 and a documented source of
infection were screened for enrolment. Patients at high risk of
death within the first 24 h after admission, systemic immu-
nosuppression, haematological diseases, metastatic cancer,
pre-existing dialysis, decompensated cirrhosis, or whoreceived more than four units of red blood cells or any fresh
frozen plasma were excluded.11 Given the stringency of the
exclusion criteria, the thresholds on SOFA and lactate were
chosen to include severe enough septic shock patients, while
ensuring adequate patient enrolment and recruitment rate.
A convenience sampled cohort of patients with sepsis
(infection with inflammatory response and one organ
dysfunction),11,12 but not in shock, was included as control.
Healthy donors were enrolled at Mutua Terrassa Hospital,
Terrassa, Spain for an additional non-sepsis control. Informed
consent was obtained from patients or proxies. Patients in the
ICU were managed according to international guidelines.13
Patient characteristics, organ function, and haemodynamic
data were prospectively collected into a custom-made elec-
tronic case report form. In-hospital mortality was assessed by
consultation of the local death registry, or by telephone call to
the patient or proxies.Sample collection
Blood (total volume 18 ml for the multiomics analyses of the
‘ShockOmics’ project)11 was collected from either the arterial or
venous line in septic shock and sepsis patients; venous blood
was drawn from healthy donors. For peptidomics, plasma (0.5
ml) was isolated within 30 min of sample collection in K2-
EDTA tubes (BD Biosciences, San Jose, CA, USA) by centrifu-
gation (twice at 1200g for 10 min) to pellet cellular elements.
COmplete Protease Inhibitor Cocktail (Roche Applied Sciences,
Mannheim, Germany) was added and samples were stored
at 80C until in-batch analyses. Plasma samples collected
from the septic shock patients at three time points were
analysed: within 16 h of ICU admission (T1); at 48 h (T2) after
ICU admission; and before discharge from the ICU or on Day 7
at latest (T3). Only one sample was collected from the sepsis
patients (at T1) and healthy donors.Liquid chromatographyemass spectrometry analysis
Residual protease activity in the plasma samples was tested by
a fluorometric assay (Supplementary material S.1). Peptides
were extracted by filtration (Supplementary material S.2),
separated by reverse phase liquid chromatography, and ana-
lysed by mass spectrometry (Supplementary material S.3) in
the Orbitrap (Thermo Fisher Scientific, Bremen, Germany).Peptide and protein identification: qualitative
approach
Proteins and peptides were identified (Supplementary
material S.4) using Mascot search engine (v2.3.01, Matrix Sci-
ence, Boston, MA, USA) against the SwissProt Human (SPH)
database (v160127). Venn diagrams of peptide counts were
generated using R packages.14Peptide and protein quantification: label-free
approach
Raw data were processed with Progenesis QI for Proteomics
(Non-Linear Dynamics, Waters, Milford, MA, USA). Pool sam-
ples were used as alignment reference. A total of 219 825 mass
spectra (z>1 and Rank<5) were considered for database search.
Mascot search engine was used against SPH (Supplementary
material S.4).
Table 1 Clinical parameters. *Mean (SD) and yn (%). Blood samples were drawn at three different time points. T1: within 16 h of ICU
admission; T2: at 48 h after ICU admission; T3: before discharge from the ICU or on Day 7 at latest. SS, septic shock
SS non-Survivors
(n¼6)
SS survivors
(n¼23)
Sepsis (n¼6) Healthy controls
(n¼9)
Age (yr)* 62e93 19e85 41e90 31e51
Sex (female)y 2 (33.3%) 7 (30.4%) 2 (33.3) 4 (44.4%)
BMI (kg m2)* 25.5 (0.93) 27.3 (6.20) 21.4 (6.43) e
SOFA*
T1 13.2 (1.94) 11.6 (2.79) 5.33 (3.01) e
T2 10.5 (3.51) 7.65 (2.62) 6.67 (3.98) e
T3 6.50 (3.62) 5.50 (3.25) e e
APACHE II* (T1) 27.2 (5.85) 23.4 (7.08) 13.0 (3.16) e
Temperature (ºC)*
T1 37.9 (1.3) 37.5 (1.3) 37.0 (0.7) e
T2 37.5 (1.1) 37.6 (0.8) 36.6 (0.4) e
T3 37.3 (2.0) 37.6 (0.9) e e
Lactate (mmol L1)*
T1 6.25 (2.94) 4.22 (2.20) 3.23 (2.79) e
T2 2.77 (0.90) 1.52 (0.64) 0.75 (0.07) e
T3 1.56 (0.51) 1.16 (0.56) e e
Heart rate (beats min1)*
T1 109 (19) 107 (26) 95 (21) e
T2 92 (25) 92 (23) 74 (32) e
T3 82 (24) 104 (19) e e
MAP (mm Hg)*
T1 59 (7) 59 (6) 80 (17) e
T2 67 (6) 67 (9) 68 (18) e
T3 73 (15) 76 (13) e e
Patients on vasopressory
T1 6 (100) 22 (95.7) 0 (0.0) e
T2 4 (66.7) 12 (52.2) 0 (0.0) e
T3 2 (33.3) 3 (21.4) 0 (0.0) e
Patients on mechanical ventilationy
T1 6 (100) 18 (78.3) 0 (0.0) e
T2 6 (100) 13 (56.5) 0 (0.0) e
T3 3 (50.0) 6 (42.9) 0 (0.0) e
Renal replacement therapyy
T1 0 (0.0) 1 (4.35) 0 (0.0) e
T2 0 (0.0) 0 (0.0) 0 (0.0) e
T3 0 (0.0) 0 (0.0) 0 (0.0) e
Source of infectiony
Abdominal 1 (16.7) 8 (34.8) 1 (16.7) e
Respiratory 5 (83.3) 7 (30.4) 3 (50.0) e
Urinary tract 0 (0.0) 8 (34.8) 2 (33.3) e
Mortalityy
ICU 5 (83.3) 0 (0.0) 0 (0.0) e
Hospital 6 (100) 0 (0.0) 0 (0.0) e
Proteolysis in septic shock and mortality - 1067Both the total number (i.e. the sum of peptides found in the
subjects belonging to a group) and the number of exclusive
peptides identified (i.e. the sum of peptides found exclusively
in such group) in the septic shock, sepsis, and heathy donor
groups were compared.
The level of proteolysis is related to the intensity of the
peptide signal detected by the mass spectrometry, which is
proportional to the peptide abundance in a sample, as calcu-
lated by Progenesis. The abundance of a cleaved protein is the
cumulative abundance of all peptides derived uniquely from
cleavage of this protein. Then, the median abundance of each
protein in a patient group is computed, and the total protein
abundance is obtained from the sum of the medians of all the
cleaved proteins in the patient group. This serves as an esti-
mate of proteolysis: an incremental change in the abundance
of cleaved proteins can be interpreted as an incremental
change in proteolysis.In silico protease effector estimation
In order to estimate the proteases responsible for protein
cleavage, we split the peptide dataset into two: protein frag-
ments with median abundance ratio higher or exclusive to
the healthy group (357 peptides) and protein fragments with
median higher or exclusive to the septic shock group (500
peptides). We extracted the C-terminus amino acid of every
identified peptide, obtaining P1C-term amino acids and P1N-term
amino acids (immediately before each peptide N-terminus
position) by matching the peptides to the SPH database using
a variant of a Perl Script.15 The analysis of proteases
responsible for both C- and N-terminus cleavage focused
specifically on matrix metalloproteases (MMPs), for their role
in shock pathophysiology,16 and on serine proteases, which
could have a dual role of cleaving proteins and activating pro-
MMPs.
Fig 1. Venn diagrams of: (A) peptides generated by proteolysis in the septic shock group (n¼29), in the sepsis group (n¼6), and in the healthy
controls (n¼9) at T1; (B) peptides generated by proteolysis in the survivor subgroup (n¼23) of the septic shock patients at the three different
time points T1, T2, and T3; (C) peptides generated by proteolysis in the non-survivors subgroup (n¼6) of the septic shock patients at the
three different time points T1, T2, and T3. Numbers in brackets indicate the number of peptides exclusively observed in each group divided
by the number of patients in each group (exclusive peptides/n). Blood samples were drawn at three different time points. T1: within 16 h of
ICU admission; T2: at 48 h after ICU admission; T3: before discharge from the ICU or on Day 7 at latest (T3).
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For group homogeneity, calculated P-values correspond to
Student’s t-test and c2 test for numerical and categorical data,
respectively.
In order to assess the spread of the data of cleaved proteins
and derived peptides, data variance was tested by one-way
analysis of variance (ANOVA) after log2-transformation of the
dataset. Proteins showing significant differences (P<0.05) be-
tween groups by the ANOVA test were evaluated for normality
through the Shapiro-Wilk test. For non-normally distributed
protein abundances, comparisons of the mean abundances
between groups were evaluated byWilcoxon (ManneWhitney)
test; for normally-distributed protein abundances, compari-
sons were evaluated by Student’s t-test (P<0.05). Statistical
analyses were performed using R packages.14Results
Study participants
Out of 529 screened patients, 29 patients with septic shock (of
whom six died during the hospital stay) and six septic controls
were enrolled in the study. Healthy blood donors (n¼9) served
as additional controls (Table 1). At T1, patients with septicshock not surviving to hospital discharge were older than
survivors (P¼0.034), with higher acute physiology and chronic
health evaluation II (APACHEII) (P¼0.00091) and SOFA
(P¼0.0005) scores than septic patients not in shock. No sig-
nificant difference in the SOFA score was found between
septic shock survivors and non-survivors at either T1 or T2. At
T2, lactate was higher (P¼0.017) in the non-survivors. No pa-
tient in the sepsis group not in shock died during the hospital
stay.
Proteolysis in septic shock
Both the total (2743) and exclusive (1855) peptide population
counts in the septic shock group at T1 were higher than in the
sepsis and healthy groups (Fig. 1A). The mean value of exclu-
sive peptides per patient was computed to account for the
different group sizes. Septic shock patients had approximately
a three-fold larger peptide population than the sepsis control
and healthy donor groups.
Septic shock peptidome: correlation with outcome and
source of infection
The mean values of the peptides exclusive for each group
(Fig. 1B and C) were lower for survivors than non-survivors at
Fig 2. Proteolysis levels at the time points T1 and T2 expressed as total abundance (see Peptide and protein quantification: label-free
approach in the Methods section) of the proteins cleaved in different patient groups, classified according to: (a) survival (S¼survivor
septic shock; NS¼non-survivor septic shock); and (b) source of infection (Uro¼urosepsis; Resp¼respiratory septic shock; Abd¼abdominal
septic shock). C¼septic control; H¼healthy donor. T1: within 16 h of ICU admission; T2: at 48 h after ICU admission.
Table 2 Source of infection and number of circulating pep-
tides. Blood samples were drawn at three different time
points. T1: within 16 h of ICU admission; T2: at 48 h after ICU
admission; T3: before discharge from the ICU or on Day 7 at
latest (T3)
Source of
infection
n Total
no.
peptides
Exclusive
peptides
Exclusive
peptides/n
Urinary tract: survivors
T1 8 1016 352 44
T2 8 885 241 30
T3 3 512 85 28
Abdominal: survivors
T1 8 1429 601 75
T2 8 1119 318 40
T3 6 785 182 30
Respiratory: survivors
T1 7 1442 522 75
T2 7 1556 663 95
T3 5 704 140 28
Proteolysis in septic shock and mortality - 1069all times. In addition, survivors showed a decrease from T1 to
T2, while the non-survivor group showed a large increase at T2,
the time when the highest peptide count was reached in non-
survivors.
To investigate the relationship between proteolysis and
outcome, we compared the peptidomes of survivors vs non-
survivors at T1 and T2. This quantitative analysis identified
218 proteins as the source for 913 peptides detected in the
plasma samples. At both time points, the proteolysis levels,
estimated from the abundance of the cleaved proteins, were
increased in the non-survivor group (Fig. 2a) vs survivors.
Further, when comparing the sources of infection, the
magnitudeofproteolysiswashigher in respiratory-initiated and
abdominal-initiated septic shock compared with urosepsis
(Fig. 2b). In the urinary and abdominal septic shock subgroups,
the numbers of total, exclusive peptides and mean of exclusive
peptides decreased from T1 to T3 (Table 2). The respiratory sub-
group displayed a different behaviour. Both survivors and non-
survivors in this subgroup presented a higher number of pep-
tides at T2 than at T1, although the increase was larger in the
non-survivors group, which displayed the highest number of
peptides at T2. Except for the respiratory non-survivors, the
number of peptides at T3 was smaller than at T1 in all groups.
No protein from the urosepsis group was characterised by
significantly increased proteolysis either at T1 or T2, while we
found five proteins subject to significantly increased proteol-
ysis in the abdominal septic shock group at T1, and 10 proteins
with significantly increased proteolysis in the group that had a
respiratory-initiated septic shock at T2 (Supplementary
Table S2).
Group differences in proteolysis levels were assessed by
computing the difference between protein abundance in the
two groups at T2 (Fig. 3), the time point at which the two groups
of survivors and non-survivors clearly separated. At T1 there
was no appreciable difference between the two groups. At T2,
six proteins showed significantly increased proteolysis in non-
survivors (Fig. 3aef), and one protein in survivors (Fig. 3g).Respiratory: non-survivors
T1 5 1265 344 69
T2 5 1689 634 127
T3 4 1252 343 86Effector proteases estimation
In total, 644 and 929 P1N/C-term amino acids for the healthy and
septic shock groups, respectively, were classified according tothe protease-specific cleavage annotated in databases17 and
the literature.7,18 Despite comparable protease cleavage dis-
tributions, the contribution of chymotrypsin-like enzymes to
proteolysis was larger in shock (42% of the circulating pep-
tides) than in the healthy controls (37%) (Fig. 4).Discussion
This study demonstrates that plasma from septic shock pa-
tients displayed approximately a three-fold increment in total
peptide count compared with healthy individuals, as well as
40% higher peptide abundance, indicating elevated proteolysis
above physiological levels in septic shock. The protein frag-
ments resulted mostly from the proteolytic action of serine
proteases, such as chymotrypsin-like enzymes, and MMPs, in
Fig 3. Boxplots representing the difference between survivors and non-survivors in protein abundance used to estimate proteolysis at T2.
Central marks in the boxplot represent median Log2 abundance, the edges represent 1st and 3rd quartiles and outliers are defined as those
observations being greater than 1.5 times the inter-quartile range (whiskers) and are plotted as a blank circle. *P-value<0.05 for Wilcoxon
(ManneWhitney) test; yP-value<0.05, and zP-value<0.01 for Student’s t-test. S: survivors; NS: non-survivors; T2: at 48 h after ICU admission.
(a) CATL1: cathepsin L1; (b) G3P: glyceraldehyde-3-phosphate dehydrogenase; (c) OIT3: oncoprotein-induced transcript 3 protein; (d) KV204:
immunoglobulin kappa variable 2D-28; (e) TIMP1: tissue inhibitor of metalloproteases 1; (f) HORN: hornerin; (g) PRB3: basic salivary proline-
rich protein 3.
1070 - Bauza-Martinez et al.accordance with previous evidence.7,19e22 The distribution of
protease effectors responsible for proteolytic cleavage in
shock was similar to the one in healthy controls: the largest
number of circulating peptides were derived by proteolytic
cleavage because of chymotrypsin-like enzymes in both
groups, while elastase-like/MMPs, and MMPs and trypsin-like
enzymes contributed to a similar extent to proteolysis in
both groups, with a slight reduction of the contribution of
MMPs and trypsin-like enzymes and a slight increase of
elastase-like/MMPs. These results: (i) hint at a pathological
shift in the concentration or activity of circulating enzymes or
in the balance between endogenous protease inhibitors (thereduced presence of which in shock could also explain the
increased proteolysis) and active proteases; (ii) confirm in
humans the concept, previously proposed in experimental
models of shock, that increased enzymatic activity and diffuse
proteolysis are associated with mortality;36,21,22 and (iii) are
consistent with previous reports on the effectiveness of anti-
protease treatments in acutely ill humans.23 Therefore, this
body of evidence points to a novel pathological mechanism
with evident therapeutic implications in the complex frame-
work of septic shock.
The comparison between non-survivors and survivors
yielded a significantly larger total number of circulating
Fig 4. Proteases acting in the proteolytic process according to the peptide datasets observed in the healthy and septic shock groups. (A)
Number (664) of P1 amino acids obtained from the 357 peptide sequences more abundant or present only in the healthy group; bar plots
represent the amount of different amino acids observed at the P1 cleavage position, including N and C-term; each letter code represents an
amino acid and each column accounts for all the cleaving sites of every enzyme listed on the x axis. (B) Number (929) of P1 amino acids
obtained from 500 peptide sequences more abundant or present only in the septic shock group (at T1 and T2); bar plots represent the
amount of different amino acids observed at the P1 cleavage position, including N and C-term; each letter code represents an amino acid
and each column accounts for all the cleaving sites of every enzyme listed on the x axis. The percentage of cleavage associated to in silico
predicted effector proteases is shown in (C) for the healthy group and in (D) for the septic shock group. T1: within 16 h of ICU admission; T2:
at 48 h after ICU admission. MMPs, matrix metalloproteases.
Proteolysis in septic shock and mortality - 1071peptides in the non-survivor group at admission to the ICU,
which increased further at 48 h after ICU admission (Figs 1 and
2). This result is even more striking in light of the low number
of subjects in the non-survivor group and reinforces the notion
that protein cleavage is increased in lethal septic shock.
Several important proteins were differentially cleaved be-
tween non-survivors and survivors. Specifically, at T2, six
proteins were more proteolysed in non-survivors, suggesting
the pathologic disruption of important biological processes
(Table 3). Most of these proteins are physiologically expressed
in multiple tissues, and they are involved in the regulation of
several functions known to be altered in shock, such as im-
mune response, complement activation, coagulation, toll-like
receptor signalling, etc. Of interest in the context of our find-
ings, several proteins are involved in the regulation of pro-
teolytic activity, especially by acting as endopeptidase
inhibitors. For instance, the increased cleavage of glyceralde-
hyde-3-phosphate dehydrogenase (Fig. 3b) may explain the
reduction of aspartic-type endopeptidase inhibitor activity,
and the increased cleavage of tissue inhibitor of metal-
loproteases 1 (Fig. 3e), a potent MMP inhibitor, may reflect a
higher release of MMP24 into plasma of non-surviving in-
dividuals. The cleavage of inhibitors (inter-alpha-trypsin in-
hibitors, alpha-1-antichymotrypsin, alpha-1-antitrypsin,
alpha-2-antiplasmin), even in the absence of significant dif-
ferences in the proteolytic levels between subgroups of pa-
tients, supports the evidence of an imbalance between the
pathologically increased proteolytic activity and thephysiological endogenous inhibitory potential, which should
trigger the testing of proteases as new therapeutic targets in
septic shock.
A fragment of the activation peptide of cathepsin L1 (resi-
dues 75e89) also had increased abundance in non-survivors
(Fig. 3a), along with immunoglobulin kappa variable 2D-28,
hornerin, and the liver-specific25 oncoprotein-induced tran-
script 3 protein.
Only one protein was more proteolysed in the survivors
group (Fig. 3g) (i.e. basic salivary proline-rich protein 3, a
salivary gland secreted protein involved in a ‘first barrier’
immune response to infection, given its role in the saliva as
receptor for the Gram-negative Fusobacterium nucleatum). The
identification of this protein is based on the qSLNEDVS-
QEESPSVISGKPEGR peptide sequence (residues 17e39 of the
protein), which corresponds to the protein N-terminus after
signal peptide release, detected with modified N-terminal
glutamine (q) to pyroglutamate.26
We also found that 10 proteins were only proteolysed in
survivors at T1 or T2, while in contrast, no protein was exclu-
sively proteolysed in non-survivors. The proteolysis of these
10 proteins (Supplementary Table S1) may have beneficial
roles in the progression of shock and be part of enhanced re-
covery in survivors. Among these proteins, a 29-amino acid
peptide fragment of lipopolysaccharide-binding protein
(P18428) was found in 57% of survivors at T1. The identification
of this protein is based on the ANPGLVAR-
ITDKGLQYAAQEGLLALQSEL peptide. As a protein that
Table 3 Significantly differently cleaved proteins between survivors and non-survivors. Protein name; origin (where the protein is
physiologically expressed); general molecular function; biological processes or pathways in which the protein is involved
Protein Origin Function Biological processes
Cathepsin L1 Lysosome Cysteine- and serine-type
endopeptidase activity; collagen,
elastin, alpha-1 protease inhibitor
binding
Intracellular proteolysis;
adaptive immune response;
toll-like receptor signalling
pathway
Oncoprotein-induced
transcript 3 protein
Liver Hepatocellular function Urate homeostasis
Immunoglobulin
kappa-variable 2D-28
Membrane-bound
or secreted
Antigen binding; serine-type
endopeptidase activity
Immune response (humoral
immunity);
immune response regulation;
complement activation
pathway
Tissue inhibitor of
metalloproteases 1
Multiple tissues Irreversible inactivation of specific
MMPs,
regulation of extracellular matrix
composition
Involvement in the regulation of
multiple processes (e.g. wound
healing,
response to cytokines,
response to
hormones, etc.)
Hornerin Cytoplasm Calcium ion binding Innate immune system
Glyceraldehyde-3-phosphate
dehydrogenase
Intracellular Aspartic-type endopeptidase
inhibitor activity, etc.
Glycolysis; nuclear functions
Basic salivary proline-rich
protein 3
Saliva Receptor for the Gram-negative
Fusobacterium nucleatum
Immune response
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receptors (e.g. CD14, TLR4),27 P18428 degradation may signal a
reduced response to Gram-negative endotoxin-mediated sig-
nalling and its absence in non-survivors could indicate com-
plete degradation of the protein into fragments below the
peptide range in the current analysis. The significance of this
protein in survival remains to be investigated with indepen-
dent measurements of LPS concentrations in patients.
Peptidomic profiles were different according to the source of
infection. Uroseptic shock typically has better prognosis than
shock derived from pulmonary or abdominal origins.28 Consis-
tently, proteolysis was more limited in the uroseptic patients,
further confirming the association between severity of septic
shock, outcome, and extent of proteolysis. Reduced proteolysis
in these patients could be related to a favourable response to the
early therapeutic interventions which, when successful, limit
hypoperfusion and protect the tissues, including the gut.29
Furthermore, in hyperdynamic states such as urosepsis, blood
flow to heart, gut, and kidney is better preserved.30
In contrast, septic shock of pulmonary origin accounted for
five of the six deaths and it was the most common source of
infection, similar to previous observations.28 Comparison of
proteolysis in abdominal and respiratory infection showed
that five proteins were significantly more cleaved in the
abdominal group at T1, while 12 proteins were significantly
more cleaved in the respiratory-initiated shock patients
(Supplementary Table S2). Despite the same overall level of
proteolysis at T1, these differences could indicate a broader
impact of proteolysis on physiologic and repair processes in
the respiratory group and therefore explain the association
between outcome and proteolysis. These observations indi-
cate that, much like in urosepsis, the patterns of proteolysis in
the pulmonary and abdominal groups were consistent with
their clinical severity.
The present study acknowledges some limitations. First,
non-survivors were on average older than survivors and ofhealthy donors. Still, the data on circulating peptides detected
in the whole septic shock group (survivors and non-survivors
together), as well as in both the abdominal and respiratory
septic shock subgroups at T1 do not point to a positive corre-
lation between age and levels of proteolysis. This is consistent
with previously reported evidence of the negative correlation
between ageing and proteasome activity,31 and of the
decreasing trypsin and MMP-9 activity with age32 (with
possible pathological implications), which is also accompa-
nied by increased alpha-1-antitrypsin concentration. Second,
the number of enrolled patients was not very large. However,
this work can serve as a guide for future studies designed to
validate the peptidomic approach and its significance in larger
and more diverse cohorts.Conclusions
We propose a novel peptidomics-based analysis to test pro-
teolysis in septic shock patients as a fundamental pathological
mechanism contributing to outcome. Our data suggest an
enhanced proteolytic activity with an association between
proteolysis and mortality.
Even though the current analysis was limited to plasma
only, the main findings of our study confirm previous animal
reports. We observed that the increased proteolysis is the
result of the activity of serine proteases and MMPs, and could
also be explained by the systematic cleavage of endogenous
protease inhibitors. Thus, a patient’s peptidomic profile could
serve as a useful tool for interpreting the trajectory and
outcome of patients in septic shock and to design new thera-
peutic treatments aimed to target proteases and support pro-
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